The vector of anti-CD37 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD37. The T cells are genetically modified through transduction with a vector expressing scFv of anti-CD37 antibody linked to CD3-zeta signaling domains. And the vector product was designed for the treatment of B cell malignancies, such as chronic lymphocytic leukemia (CLL), B cell non-Hodgkin lymphoma (B cell NHL), hairy cell leukemia (HCL), acute lymphoblastic leukemia (ALL) and lymphoplasmacytic lymphoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|VP-CAR-LC114||Lenti-CD37 CAR (scFv-CD4-FcεRIγ, G28-1) Viral Particle|
|VP-CAR-LC109||Lenti-CD37 CAR (scFv-CD28, G28-1) Viral Particle|
|VP-CAR-LC110||Lenti-CD37 CAR (scFv-FcεRIγ, G28-1) Viral Particle|
|VP-CAR-LC113||Lenti-CD37 CAR (scFv-CD28-CD3ζ, G28-1) Viral Particle|
|CAR-T-3-L333-2BZ||Anti-CD37 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1|
|CAR-T-2-L333-BZ||Anti-CD37 scFv h(41BB-CD3ζ) CART, pCDCAR1|
|VP-CAR-LC115||Lenti-CD37 CAR (scFv-CD4-CD3ζ, G28-1) Viral Particle|
|VP-CAR-LC111||Lenti-CD37 CAR (scFv-CD3ζ, G28-1) Viral Particle|
|CAR-T-2-L333-4Z||Anti-CD37 scFv h(CD4-CD3ζ) CART, pCDCAR1|
|CAR-T-1-L333-2||Anti-CD37 scFv h(CD28) CART, pCDCAR1|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved